Articolo di Review(s)
V. 11 (2023)
Revisione sulle Interstiziopatie Polmonari: una panoramica dalla diagnosi alle terapie innovative
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
##plugins.generic.dates.received##: 29 giugno 2023
##plugins.generic.dates.accepted##: 20 luglio 2023
##plugins.generic.dates.accepted##: 20 luglio 2023
1347
Visite
320
Downloads
Autori
Le interstiziopatie polmonari (ILD) racchiudono un ampio gruppo eterogeneo di oltre 200 disturbi patologici, caratterizzati da un quadro infiammatorio e/o fibrotico a carico delle vie respiratorie.
Negli ultimi anni, gli importanti sviluppi nella comprensione della loro patogenesi hanno portato a notevoli progressi in campo terapeutico ed al miglioramento degli esiti clinici.
La pandemia COVID-19 ha avuto un impatto importante anche sul decorso della malattia interstiziale, in particolare quella sviluppatasi in seguito all'infezione sia in pazienti sintomatici che asintomatici, nonché in pazienti con malattia interstiziale pre-esistente all'infezione.
Lo scopo di questa revisione è quello di descrivere le caratteristiche cliniche, radiologiche e terapeutiche di alcune delle più comuni interstiziopatie polmonari, nonché l'iter diagnostico multidisciplinare alla base di una diagnosi sempre più accurata.
Downloads
La data di download non è ancora disponibile.
Citations
Wijsenbeek M, Suzuki A, Maher TM. Interstitial lung diseases. Lancet. 2022;400:769-86. DOI: https://doi.org/10.1016/S0140-6736(22)01052-2
Bagnato G, Harari S. Cellular interactions in the pathogenesis of interstitial lung diseases. Eur Respir Rev. 2015;24:102-14. DOI: https://doi.org/10.1183/09059180.00003214
Shumar JN, Chandel A, King CS. Antifibrotic Therapies and Progressive Fibrosing Interstitial Lung Disease (PF-ILD): Building on INBUILD. J Clin Med. 2021;10:2285. DOI: https://doi.org/10.3390/jcm10112285
Behr J, Kreuter M, Hoeper MM, et al. Management of patients with idiopathic pulmonary fibrosis in clinical practice: the INSIGHTS-IPF registry. Eur Respir J. 2015;46:186-96. DOI: https://doi.org/10.1183/09031936.00217614
Raghu G, Amatto VC, Behr J, Stowasser S. Comorbidities in idiopathic pulmonary fibrosis patients: a systematic literature review. Eur Respir J. 2015;46:1113-30. DOI: https://doi.org/10.1183/13993003.02316-2014
Mikolasch TA, Garthwaite HS, Porter JC. Update in diagnosis and management of interstitial lung disease. Clin Med (Lond). 2017;17:146-53. DOI: https://doi.org/10.7861/clinmedicine.17-2-146
Raghu G, Remy-Jardin M, Myers JL, et al. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. Am J Respir Crit Care Med. 2018;198:e44-68. DOI: https://doi.org/10.1164/rccm.201807-1255ST
Fernández Pérez ER, Swigris JJ, Forssén AV, et al. Identifying an inciting antigen is associated with improved survival in patients with chronic hypersensitivity pneumonitis. Chest. 2013;144:1644-51. DOI: https://doi.org/10.1378/chest.12-2685
Raghu G, Remy-Jardin M, Richeldi L, et al. Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. Am J Respir Crit Care Med. 2022;205:e18-47. DOI: https://doi.org/10.1164/rccm.202202-0399ST
Maher TM, Bendstrup E, Dron L, et al. Global incidence and prevalence of idiopathic pulmonary fibrosis. Respir Res. 2021;22:197. DOI: https://doi.org/10.1186/s12931-021-01791-z
Travis WD, Costabel U, Hansell DM, et al. An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med. 2013;188:733-48. DOI: https://doi.org/10.1164/rccm.201308-1483ST
Sève P, Pacheco Y, Durupt F, et al. Sarcoidosis: A Clinical Overview from Symptoms to Diagnosis. Cells. 2021;10:766. DOI: https://doi.org/10.3390/cells10040766
Ketchersid K. A review of organizing pneumonia. JAAPA. 2023;36:16-9. DOI: https://doi.org/10.1097/01.JAA.0000918776.59717.eb
Qi XM, Luo Y, Song MY, et al. Pneumoconiosis: current status and future prospects. Chin Med J (Engl). 2021;134:898-907. DOI: https://doi.org/10.1097/CM9.0000000000001461
Raghu G, Remy-Jardin M, Ryerson CJ, et al. Diagnosis of Hypersensitivity Pneumonitis in Adults. An Official ATS/JRS/ALAT Clinical Practice Guideline. Am J Respir Crit Care Med. 2020;202:e36-69. Erratum in: Am J Respir Crit Care Med. 2021;203:150-1. Erratum in: Am J Respir Crit Care Med. 2022;206:518. DOI: https://doi.org/10.1164/rccm.v203erratum1
Kadura S, Raghu G. Rheumatoid arthritis-interstitial lung disease: manifestations and current concepts in pathogenesis and management. Eur Respir Rev. 2021;30:210011. DOI: https://doi.org/10.1183/16000617.0011-2021
Cavagna L, Monti S, Grosso V, et al. The multifaceted aspects of interstitial lung disease in rheumatoid arthritis. Biomed Res Int. 2013;2013:759760. DOI: https://doi.org/10.1155/2013/759760
Juge PA, Lee JS, Ebstein E, et al. MUC5B Promoter Variant and Rheumatoid Arthritis with Interstitial Lung Disease. N Engl J Med. 2018;379:2209-19. DOI: https://doi.org/10.1056/NEJMoa1801562
Wang D, Zhang J, Lau J, et al. Mechanisms of lung disease development in rheumatoid arthritis. Nat Rev Rheumatol. 2019;15:581-96. DOI: https://doi.org/10.1038/s41584-019-0275-x
Young A, Vummidi D, Visovatti S, et al. Prevalence, Treatment, and Outcomes of Coexistent Pulmonary Hypertension and Interstitial Lung Disease in Systemic Sclerosis. Arthritis Rheumatol. 2019;71:1339-49. DOI: https://doi.org/10.1002/art.40862
Perelas A, Silver RM, Arrossi AV, Highland KB. Systemic sclerosis-associated interstitial lung disease. Lancet Respir Med. 2020;8:304-20. DOI: https://doi.org/10.1016/S2213-2600(19)30480-1
Fujisawa T. Management of Myositis-Associated Interstitial Lung Disease. Medicina (Kaunas). 2021;57:347. DOI: https://doi.org/10.3390/medicina57040347
Fujisawa T, Hozumi H, Kono M, et al. Prognostic factors for myositis-associated interstitial lung disease. PLoS One. 2014;9:e98824. DOI: https://doi.org/10.1371/journal.pone.0098824
Lee CT, Strek ME. The other connective tissue disease-associated interstitial lung diseases: Sjogren's syndrome, mixed connective tissue disease, and systemic lupus erythematosus. Curr Opin Pulm Med. 2021;27:388-95. DOI: https://doi.org/10.1097/MCP.0000000000000791
Sogkas G, Hirsch S, Olsson KM, et al. Lung Involvement in Primary Sjögren's Syndrome-An Under-Diagnosed Entity. Front Med (Lausanne). 2020;7:332. DOI: https://doi.org/10.3389/fmed.2020.00332
Reiseter S, Gunnarsson R, Mogens Aaløkken T, et al. Progression and mortality of interstitial lung disease in mixed connective tissue disease: a long-term observational nationwide cohort study. Rheumatology (Oxford). 2018;57:255-62. DOI: https://doi.org/10.1093/rheumatology/kex077
Narváez J, Borrell H, Sánchez-Alonso F, et al. Primary respiratory disease in patients with systemic lupus erythematosus: data from the Spanish rheumatology society lupus registry (RELESSER) cohort. Arthritis Res Ther. 2018;20:280. DOI: https://doi.org/10.1186/s13075-018-1776-8
Toyoda Y, Koyama K, Kawano H, et al. Clinical features of interstitial pneumonia associated with systemic lupus erythematosus. Respir Investig. 2019;57:435-43. DOI: https://doi.org/10.1016/j.resinv.2019.04.005
Guler SA, Ryerson CJ. Unclassifiable interstitial lung disease: from phenotyping to possible treatments. Curr Opin Pulm Med. 2018;24:461-8. DOI: https://doi.org/10.1097/MCP.0000000000000509
O'Callaghan M, Bonella F, McCarthy C. Unclassifiable, or simply unclassified interstitial lung disease? Curr Opin Pulm Med. 2021;27:405-13. DOI: https://doi.org/10.1097/MCP.0000000000000801
Skeoch S, Weatherley N, Swift AJ, et al. Drug-Induced Interstitial Lung Disease: A Systematic Review. J Clin Med. 2018;7:356. DOI: https://doi.org/10.3390/jcm7100356
Conte P, Ascierto PA, Patelli G, et al. Drug-induced interstitial lung disease during cancer therapies: expert opinion on diagnosis and treatment. ESMO Open. 2022;7:100404. DOI: https://doi.org/10.1016/j.esmoop.2022.100404
Richeldi L, Costabel U, Selman M, et al. Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. N Engl J Med. 2011;365:1079-87. DOI: https://doi.org/10.1056/NEJMoa1103690
Distler O, Highland KB, Gahlemann M, et al. SENSCIS Trial Investigators. Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease. N Engl J Med. 2019;380:2518-28. DOI: https://doi.org/10.1056/NEJMoa1903076
Wells AU, Flaherty KR, Brown KK, et al. INBUILD trial investigators. Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial. Lancet Respir Med. 2020;8:453-60. DOI: https://doi.org/10.1016/S2213-2600(20)30036-9
Noble PW, Albera C, Bradford WZ, et al. CAPACITY Study Group. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet. 2011;377:1760-9. DOI: https://doi.org/10.1016/S0140-6736(11)60405-4
Khanna D, Albera C, Fischer A, et al. An Open-label, Phase II Study of the Safety and Tolerability of Pirfenidone in Patients with Scleroderma-associated Interstitial Lung Disease: the LOTUSS Trial. J Rheumatol. 2016;43:1672-9. DOI: https://doi.org/10.3899/jrheum.151322
Behr J, Prasse A, Kreuter M, et al. RELIEF investigators. Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised, placebo-controlled, phase 2b trial. Lancet Respir Med. 2021;9:476-86. DOI: https://doi.org/10.1016/S2213-2600(20)30554-3
Podolanczuk AJ, Wong AW, Saito S, et al. Update in Interstitial Lung Disease 2020. Am J Respir Crit Care Med. 2021;203:1343-52. DOI: https://doi.org/10.1164/rccm.202103-0559UP
John AE, Joseph C, Jenkins G, Tatler AL. COVID-19 and pulmonary fibrosis: A potential role for lung epithelial cells and fibroblasts. Immunol Rev. 2021;302:228-40. DOI: https://doi.org/10.1111/imr.12977
Shi H, Han X, Jiang N, et al. Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study. Lancet Infect Dis. 2020;20:425-34. DOI: https://doi.org/10.1016/S1473-3099(20)30086-4
Valenzuela C, Waterer G, Raghu G. Interstitial lung disease before and after COVID-19: a double threat? Eur Respir J. 2021;58:2101956. DOI: https://doi.org/10.1183/13993003.01956-2021
Come citare
Revisione sulle Interstiziopatie Polmonari: una panoramica dalla diagnosi alle terapie innovative. (2023). Working Paper of Public Health, 11(1). https://doi.org/10.4081/wpph.2023.9785
Copyright (c) 2023 Carlotta Bertolina, Marinella Bertolotti, Marianna Farotto, Fabio Giacchero, Silvia Ravera, Mario Salio, Mercedes Pasquali, Antonio Maconi
Questo volume è pubblicato con la licenza Creative Commons Attribuzione - Non commerciale 4.0 Internazionale.
